Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2026 | Buy → Hold | D. Boral Capital | |
| 9/29/2025 | $2.00 | Buy | Chardan Capital Markets |
| 9/20/2023 | $12.00 | Buy | ROTH MKM |
| 6/8/2023 | $17.00 | Speculative Buy | The Benchmark Company |
| 1/24/2022 | $10.00 | Buy | HC Wainwright & Co. |
| 7/26/2021 | $10.00 | Buy | Maxim Group |
SCHEDULE 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
10-Q - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold
Chardan Capital Markets initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $2.00
ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings
CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD., Founder, President and CEO, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 24th, 2026. DATE: June 24th TIME: 1:30 PM ET REGISTER HERE Reviva Management is available for 1x1 meetings: June 26 and June 30. To schedule 1x1 Meetings, please click here The event will be conducted
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.'s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026. Fireside Chat Details: Time: 2:40-3:00 PM ETDate: Wednesday, May 20, 2026 Investors can register for the conference and vie
4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John
- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant and clinically meaningful reductions in all major symptom domains and secondary endpoints at week 4 with 50 mg of brilaroxazine vs. placebo - - Generally well-tolerated with a side effect profile comparable to placebo for the 15 and 50 mg doses of brilaroxazine; discontinuation rates for brilaroxazine lower than placebo - - Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 - - Conference call and webcast
ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip
ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel
SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
SC 13D/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)